BioSpace News Archive

Precision BioSciences, Inc. announced that, on February 9, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.

Can-Fite BioPharma Ltd. announced that Purinergic Signalling, a peer-reviewed scientific journal focused on molecules which target adenosine receptors, published an article titled “Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects” authored by Can-Fite’s CEO Dr.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that the United States (U.S.) Food and Drug Administration (FDA) has provided the Company with a Refusal to File (RTF) letter for its HyBryte™ (synthetic hypericin) new drug application (NDA) in the treatment of early stage cutaneous T-cell lymphoma (CTCL).

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat.

Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced its collaboration with two partners that will help expedite the company’s drug development pipeline.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the appointments of two pharmaceutical industry veterans to its executive leadership team.

Ferring Pharmaceuticals today announced that REBYOTA™ (fecal microbiota, live – jslm) is now available in the United States (U.S.). REBYOTA is the first and only microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Thylacine Biotherapeutics Inc. (“Thylacine Bio”), a privately held biotech company dedicated to combating infectious disease, announced today it has entered into a license agreement with Columbia University (“Columbia”) for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform.

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, and Analytik Jena today announced a co-marketing agreement that will allow the companies to promote applications of their combined laboratory automation technologies that will enable customers to accelerate and optimize their scientific research.